- Home
- CBNA vs CLLS Comparison
CBNA vs CLLS Comparison
Compare CBNA & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- CLLS
- Stock Information
- Founded
- CBNA 2006
- CLLS 1999
- Country
- CBNA United States
- CLLS France
- Employees
- CBNA N/A
- CLLS N/A
- Industry
- CBNA
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- CBNA
- CLLS Health Care
- Exchange
- CBNA NYSE
- CLLS Nasdaq
- Market Cap
- CBNA 159.8M
- CLLS 148.1M
- IPO Year
- CBNA 2024
- CLLS 2007
- Fundamental
- Price
- CBNA $24.48
- CLLS $1.45
- Analyst Decision
- CBNA Buy
- CLLS Buy
- Analyst Count
- CBNA 3
- CLLS 3
- Target Price
- CBNA $29.67
- CLLS $7.00
- AVG Volume (30 Days)
- CBNA 14.0K
- CLLS 120.5K
- Earning Date
- CBNA 05-15-2025
- CLLS 05-27-2025
- Dividend Yield
- CBNA N/A
- CLLS N/A
- EPS Growth
- CBNA 115.79
- CLLS N/A
- EPS
- CBNA 4.17
- CLLS N/A
- Revenue
- CBNA $53,113,000.00
- CLLS $49,217,000.00
- Revenue This Year
- CBNA N/A
- CLLS $1.26
- Revenue Next Year
- CBNA $22.92
- CLLS N/A
- P/E Ratio
- CBNA $5.87
- CLLS N/A
- Revenue Growth
- CBNA 74.81
- CLLS 435.38
- 52 Week Low
- CBNA $20.01
- CLLS $1.10
- 52 Week High
- CBNA $27.56
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- CLLS 60.38
- Support Level
- CBNA N/A
- CLLS $1.40
- Resistance Level
- CBNA N/A
- CLLS $1.56
- Average True Range (ATR)
- CBNA 0.00
- CLLS 0.09
- MACD
- CBNA 0.00
- CLLS 0.03
- Stochastic Oscillator
- CBNA 0.00
- CLLS 76.09
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.